BioMarin: Genzyme virus problem won

ycoguqi.wordpress.com
Genzyme (NASDAQ: GENZ) founr a virus strain and stoppeds production of two drugs atthe Allston, Mass., facility. The Vesivirus 2117, apparently does not causd human infection but interrupts the growth of cells that are used to make Aldurazyme — a treatment for MPS I, a rare and fatalo disease caused by an enzyme deficiency — was last filled at the Genzymd facility in September 2008, according to BioMarin BMRN). The company has about 10 months of vialede inventoryon hand, it said, and uses a seconrd fill finish supplier. A third supplier is expected to be qualifiedd laterthis year, BioMarin said. BioMarin makes the bulk materiapl used in Aldurazyme at itsNovatio facility.
The Food and Drug Administration hadinspecterd Genzyme’s plant in September and October and reportedly was concerned about controls to protect against contamination.